Better Health for All

Moleculin Biotech's entire business is devoted to developing therapies for hard-to-treat cancers and pathogenic viruses, with all products aiming to provide substantial health benefits, including Annamycin for AML and STS, WP1066 for brain tumors, and WP1122 for viruses.

Annamycin has demonstrated no cardiotoxicity in 90 subjects across five clinical trials, even at doses exceeding the FDA's lifetime maximum, which is a significant safety improvement over existing anthracyclines. However, two adverse events (allergic reactions) were reported in one AML trial, and two subjects experienced asymptomatic adverse events meeting stoppage criteria in a WP1122 Phase 1a trial. The company offers expanded access to investigational products for patients with serious or life-threatening diseases when other options are exhausted, and the MIRACLE trial is global, including sites in the US, Europe, and the Middle East. However, the company is not currently prioritizing the development of WP1096 for antivirals over oncology initiatives. The company's risk transparency includes forward-looking statements and mentions risks detailed in SEC filings, but does not provide comprehensive public data resources for all health claims. The MIRACLE trial is a randomized, double-blind, placebo-controlled study, registered on clinicaltrials.gov and euclinicaltrials.eu, and includes an adaptive design for dose optimization. The company holds composition of matter patent protection for Annamycin until 2040, with potential extension to 2045, but no information on patent flexibility for global health needs is provided. The company's operations generate positive health externalities by developing a drug (Annamycin) designed to lack cardiotoxicity, addressing the issue that nearly half of all cancers are treated with cardiotoxic anthracyclines.

Fair Pay & Worker Respect

Moleculin Biotech, Inc. had 17 employees as of December 31, 2024.

While CEO total compensation for 2024 was reported as $1,458,759, there is no data on median employee compensation, preventing the calculation of a CEO-median pay ratio. No specific, quantitative data was provided in the articles for any other Fair Pay & Worker Respect KPIs, including living wage coverage, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, voluntary turnover rate, labor violation incidents, insecure contract share, or health insurance coverage. Therefore, no KPIs can be scored.

Fair Trade & Ethical Sourcing

No specific, concrete evidence regarding fair trade certifications, audit frequency, forced or child labor incidents, traceability coverage, remediation speed, ethical clause coverage, materials risk index, or supplier diversity spend was found in the provided article.

The article is identified as a code of conduct and does not contain data on actual ethical sourcing practices.

Honest & Fair Business

Moleculin Biotech, Inc. provides an Ethics Hotline, Fax Number, and Email Address for anonymous reporting, but there is no evidence of independent investigation processes.

The company's board of directors has 5 out of 6 members identified as independent under Nasdaq Rules, which equates to approximately 83.33% conflict-free directors. An anti-corruption policy is in place, prohibiting gifts or benefits of significant value (defined as over $500) without pre-approval, but the available evidence does not provide clear guidance on facilitation payments or comprehensive gift thresholds.

No War, No Weapons

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses, including acute myeloid leukemia, soft tissue sarcoma lung metastases, brain tumors, pancreatic cancer, and other viral indications.

The provided articles describe the company's drug development programs and corporate information. No evidence is available in the articles regarding the company's involvement in arms manufacturing, military contracts, dual-use technologies, sales to embargoed regimes, peacebuilding investments, or any other activities related to the 'No War, No Weapons' value. Therefore, no KPIs can be scored based on the provided information.

Planet-Friendly Business

No specific sustainability data is available for Moleculin Biotech, Inc. across any of the assessed Planet-Friendly Business KPIs.

The provided articles indicate a complete absence of quantitative sustainability data, regulatory actions, violations, fines, compliance issues, certifications, awards, or recognitions related to environmental performance.

Safe & Smart Tech

The company's privacy policy states it collects only personal information voluntarily provided by users, indicating a commitment to limiting data collection.

It also notes the use of cookies with unique identifiers and IP addresses for aggregate reporting and website improvement. Personal data may be transferred to third parties for processing in connection with the company's business, consistent with the original collection purposes.

Zero Waste & Sustainable Products

No specific, concrete data points or initiatives related to waste management, product recyclability, packaging sustainability, or other zero waste and sustainable product metrics for MBRX.US were found in the provided articles.

Several articles explicitly state that sustainability data for MBRX.US is currently unavailable, or that no information is available regarding regulatory actions, violations, fines, or compliance issues. Therefore, no KPIs can be scored based on the provided evidence.